Zealand University Hospital, Roskilde is the main hospital in Roskilde on the Danish island of Zealand. It should not be confused with Zealand University Hospital, Køge. Zealand University Hospital, Roskilde was founded in 1855, and as of 2014 it had 437 beds for in-patients and several specialist wards.

During the past decade, Roskilde Hospital conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 15 clinical trials were completed, i.e. on average, 31.9% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 9 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Roskilde Hospital" #1 sponsor was "Rigshospitalet, Denmark" with 8 trials, followed by "Zealand University Hospital" with 7 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Bayer" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Roskilde Hospital" #1 collaborator was "Zealand University Hospital" with 8 trials as a collaborator, "Rigshospitalet, Denmark" with 5 trials as a collaborator, "Aarhus University Hospital" with 4 trials as a collaborator, "AbbVie" with 4 trials as a collaborator and "Odense University Hospital" with 4 trials as a collaborator. Other collaborators include 79 different institutions and companies that were collaborators in the rest 76 trials.

According to Clinical.Site data, the most researched conditions in "Roskilde Hospital" are "Metastatic Colorectal Cancer" (3 trials), "Acute Leukemia" (2 trials), "COVID-19" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials) and "Colon Cancer" (2 trials). Many other conditions were trialed in "Roskilde Hospital" in a lesser frequency.

Most popular intervention types in "Roskilde Hospital" are "Drug" (41 trials), "Other" (13 trials), "Procedure" (7 trials), "Biological" (5 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Venetoclax" (5 trials), "Obinutuzumab" (3 trials), "Azithromycin" (2 trials) and "BI 685509" (2 trials). Other intervention names were less common.

The vast majority of trials in "Roskilde Hospital" are 70 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 29 active trials in "Roskilde Hospital". 1 are not yet recruiting, 18 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 32 completed trials in Roskilde Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Roskilde Hospital, 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 15 trials that are defined as “Not Applicable".